Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon

Pediatric Infectious Disease Journal

Volumn 30, Issue 12, 2011, Pages 1062-1068

  Fokam, Joseph ^a,b   Salpini, Romina ^c   Santoro, Maria Mercedes ^c   Cento, Valeria ^c   Perno, Carlo Federico ^c   Colizzi, Vittorio ^a,d   Ndumbe, Peter Martins ^a,b,e   Fokunang Ntungen, Charles ^b   Ndiang Tetang, Suzie Moyo ^f   Nanfack, Aubin Joseph ^a   Takou Komego, Désiré Augustin ^a   Cappelli, Giulia ^a,g  

^a Chantal Biya International Reference Centre   (Cameroon)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCSS Lazarro Spallanzani   (Italy)

^e UNIVERSITY OF BUEA   (Cameroon)

^f Pediatric Unit   (Cameroon)

^g CNR   (Italy)

Author keywords

antiretroviral drug resistance; Cameroon; children; human immunodeficiency virus

Indexed keywords

LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CAMEROON; CHILD; CLADISTICS; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; PHYLOGENY; PRIORITY JOURNAL; VIREMIA;

ANTI-HIV AGENTS; CAMEROON; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; PHYLOGENY; PREVALENCE; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 81855221740     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31822db54c     Document Type: Article

References (55)

1. World Health Organization. AIDS epidemic updates, December 2010. Available at: www.whoint/hiv.
2. Boyer S, Eboko F, Camara M, et al. Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS. 2010;24(suppl 1):5-15.
3. WHO/UNAIDS. "Universal access to comprehensive prevention programs, treatment, care and support" by 2010. 2006. Available at: wwwwhoint/hiv.
4. Cameroon Ministry of Health. National AIDS control Programme. WHO/HIV Drug Resistance Working Group Report 2010.
5. World Health Organization revision. Antiretroviral therapy for HIV infection in children and infants: toward universal access. Recommendations for public health approach. 2010. Available at: wwwwhoint/hiv.
6. Vergne L, Laurent C, Kouanfack C, et al. Effectiveness and safety of a generic fixed dose combination of stavudine, lamivudine and nevirapine in HIV-1 infected adults in Cameroon: open label multicentric trial. Lancet. 2004;364:29-34.
7. Vergne L, Kouanfack C, Aghokeng A, et al. HIV-1 drug resistance mutations among newly diagnosed patients before scaling up in Burkina Faso and Cameroon. Antivir Ther. 2006;11:575-579. (Pubitemid 44277422)
8. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine. AIDS. 2007;21:768-771. (Pubitemid 46568637)
9. Laurent C, Kouanfack C, Vergne L, et al. Antiretroviral drug resistance and routine therapy, Cameroon. Emerg Infect Dis. 2006;12:1001-1004. Available at: www.cdc.gov/eld. (Pubitemid 43848428)
10. Aghokeng FA, Vergne L, Mpoudi NE, et al. Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries. Antivir Ther. 2009;14:401-411.
11. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviralresistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for secondline treatment. Clin Infect Dis. 2009;48:1318-1322.
12. Cameroon Ministry of Public Health. Guidelines for the management of pediatric HIV infection, 2007. Available at: http://www.minsante.cm.
13. Fokam J, Salpini R, Santoro MM, et al. Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol. 2011;156:1235-1243.
14. Chaix ML, Ekouevi DK, Peytavin G, et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received singledose nvp to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob Agents Chemother. 2007;51:896-901. (Pubitemid 46355273)
15. Flys TS, McConnell MS, Matovu F, et al. Nevirapine resistance in women and infants after first versus repeated use of single dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis. 2008;198:465-469.
16. World Health Organization. Revised principles and recommendations on HIV and infant feeding. Geneva, Switzerland: World Health Organization; 2010.
17. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899. (Pubitemid 350005233)
18. Machado DM, Fernandes SC, Succi RC, et al. Analysis of HIV-type1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART). Rev Inst Med Trop Sao Paulo. 2005;47: 1-5. (Pubitemid 40314341)
19. Eshleman SH, Krogstad P, Jackson JB, et al. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). J Infect Dis. 2001; 183:1732-1738. (Pubitemid 32523235)
20. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Oragnisation/HIV ResNet drug resistance laboratory strategy. Antiviral Ther. 2008; 13(suppl 2):49-57. (Pubitemid 352019089)
21. World Health Organization. HIV Drug Resistance Early Warning Indicators; World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites; June 2010 Update. Geneva, Switzerland: World Health Organization; 2010.
22. Jordan MR, Bennett DE, Bertagnolio S, et al. World Health Organization survey to monitor HIV drug resistance prevention and associated factors in sentinel treatment sites. Antivir Ther. 2008;13(supp2):15-23. (Pubitemid 352019086)
23. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for the surveillance of transmitted HIV drug resistance in countries scaling antiretroviral treatment. Antivir Ther. 2008;13(suppl 2):25-36. (Pubitemid 352019087)
24. Easterbrook P. HIV drug resistance in HIV-infected children. J Pediatr (Rio J). 2009;85:94-96.
25. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, et al. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J Trop Med Public Health. 2009;40:83-88.
26. Gupta RK, Gibb D, Pillay D, et al. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis. 2009;22:256-263.
27. Mullen J, Leech S, O'Shea S, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol. 2002;68:299-304.
28. Church JD, Omer SB, Guay LA, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis. 2008;198:1075-1082.
29. Lwembe R, Ochieng W, Panikulam A, et al. Anti-Retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol. 2007;79:865-872. (Pubitemid 46871541)
30. Schmitz T, Kleinkauf N, Klempa B, et al. Transmission of human immunodeficiency virus type 1 mutation K103N from a treatment-naïve mother to her child. Pediatr Infect Dis J. 2006;25:275-276. (Pubitemid 43379076)
31. Wallis CL, Erasmus L, Varughese S, et al. Emergence of drug resistance in HIV-1 subtype C infected children failing the South-African National Antiretroviral roll-out program. Pediatr Infect Dis J. 2009;28:1123-1125.
32. Emmett SD, Cunningham CK, Mmbaga BT, et al. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. J Acquir Immune Defic Syndr. 2010;54: 368-375.
33. Chaix M-L, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d'Ivoire. Pediatr Infect Dis J. 2005;24:1072-1076. (Pubitemid 43011063)
34. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010;304:1082-1890.
35. Vallari A, Holzmayer V, Harris B, et al. Confirmation of putative HIV-1 group 1 P in Cameroon. J Virol. 2011;85:1403-1407.
36. Hall T. 2001. Bioedit version 5.0.6. Department of Microbiology, North Carolina State University. Available at: www.mbio.ncsu.edu/BioEdit/bioedit.html.
37. Swofford DL. PAUP: phylogenetic analysis using parsimony (and other methods): version 40. Sunderland, MA: Sinauer Associates; 2002.
38. Posada D, Buckley TR. Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests. Syst Biol. 2004;53:793-808. (Pubitemid 39568279)
39. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol. 2003;52:696-704. (Pubitemid 37365050)
40. Kosakovsky PS, Posada D, Stawiski E, et al. An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 2009;5:e1000581.
41. Struck D, Perez BD, Devaux C, et al. COMET: a novel approach to HIV-1 subtype prediction. In: 8th European HIV Drug Resistance Workshop; March 17-19, 2010; Sorrento, Italy. Abstract 88.
42. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;73:152-160. (Pubitemid 28565356)
43. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol. 2006;23:254-267. (Pubitemid 43100040)
44. Gifford RJ, Liu TF, Rhee S-Y, et al. The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics. 2009;25:1197-1198.
45. Vallari A, Bodelle P, Ngansop C, et al. Four new HIV-1 group N isolates from Cameroon: the prevalence continues to be low. AIDS Res Hum Retroviruses. 2010;26:109-115.
46. World Health Organization (WHO). Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Geneva, Switzerland: World Health Organization; 2010.
47. Johnson JA, Li J-F, Wei X, et al. Minority drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158.
48. Shafer RW. Low-abundance drug-resistant HIV-1 variants: finding significance in an era of abundant diagnostic and therapeutic options. J Infect Dis. 2009;199:610-612.
49. Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drugresistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis. 2009;201:662-671.
50. Simen BB, Simons JF, Hullsiek KH, et al. Low abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patient significantly impact treatment outcomes. J Infect Dis. 2009;199: 693-701.
51. TEmAA ANRS 12109 Study Group, Arrivé E, Chaix ML, et al. Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance. AIDS. 2010;24:2481-2488.
52. Resino S, Bellon JM, Ramos JT, et al. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23:923-930. (Pubitemid 40812779)
53. Ramos JT, De José MI, Duenas J, et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals on behalf of the Spanish Collaborative Group on HIV infection in children. Pediatr Infect Dis J. 2005;24:867-873. (Pubitemid 41475920)
54. Oliveira R, Krauss M, Essama-Bibi S, et al. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value. Clin Infect Dis. 2010;51:1325-1333.
55. Resino S, Alvaro-Meca A, De José MI, et al. Low immunologic response to active antiretroviral therapy in naive vertically human immunodeficiency virus type 1-infected children with severe immunodeficiency. Pediatr Infect Dis J. 2006;25:365-368.